Immuron Ltd (IMRN)
NASDAQ:IMRN
Want to see IMRN full AI Analyst Report?
IMRN Stock Chart & Stats
$0.82
-$0.03(-1.20%)
At close: 4:00 PM EST
$0.82
-$0.03(-1.20%)
Day’s Range― - ―
52-Week Range$0.68 - $2.39
Previous CloseN/A
Volume5.19K
Average Volume (3M)75.95K
Market Cap
$10.76M
Enterprise Value$317.80K
Total Cash (Recent Filing)$9.99M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.12
Next Earnings
Aug 28, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding8,166,340
10 Day Avg. Volume112,552
30 Day Avg. Volume75,952
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)1.90
Price to Sales (P/S)2.09
P/FCF Ratio-2.49
Enterprise Value/Market Cap0.03
Enterprise Value/Revenue0.04
Enterprise Value/Gross Profit0.06
Enterprise Value/Ebitda-0.05
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)$6.66M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Conservative Balance SheetA debt-to-equity of 0.0145 indicates minimal leverage, reducing fixed financing costs and default risk. For a biotech with elongated development timelines, a conservative capital structure preserves strategic optionality to fund trials or commercialization via equity or partnerships without heavy interest burdens.
Stable High Gross MarginsGross margins near 65% suggest the core colostrum-derived product economics are strong and scalable. Once R&D and SG&A are managed or spread across higher volumes, these durable product-level margins can support positive operating leverage and eventual profitability as sales scale.
Existing Commercial Product And Diversified Revenue SourcesHaving an on-market product (Travelan) generates recurring retail and distributor revenue and provides a commercial foothold while pipeline programs mature. Coupled with potential collaboration or milestone income, this reduces binary clinical risk and offers multiple funding channels over the medium term.
Bears Say
Declining Revenue And Persistent LossesAn 11% revenue decline combined with deeply negative profitability metrics indicates the company is struggling to grow sales and absorb fixed costs. Persistent losses erode equity, limit reinvestment in R&D/commercial expansion, and increase reliance on external funding or partnerships over time.
Negative Operating And Free Cash FlowSustained negative operating and free cash flow with a steep -31.37% FCF contraction indicate structural cash burn. This constrains the firm's ability to self-fund trials, scale manufacturing or commercial efforts, and raises the probability of future dilution or the need for non-dilutive partnerships.
Very Small Operational ScaleA headcount of seven implies limited internal capacity for R&D, regulatory, manufacturing oversight, and commercial execution. This increases dependence on external partners or contractors, can slow program timelines, and raises execution risk for expanding sales or advancing multiple pipeline candidates concurrently.
Immuron News
IMRN FAQ
What was Immuron Ltd’s price range in the past 12 months?
Immuron Ltd lowest stock price was $0.68 and its highest was $2.39 in the past 12 months.
What is Immuron Ltd’s market cap?
Immuron Ltd’s market cap is $10.76M.
When is Immuron Ltd’s upcoming earnings report date?
Immuron Ltd’s upcoming earnings report date is Aug 28, 2026 which is in 85 days.
How were Immuron Ltd’s earnings last quarter?
Immuron Ltd released its earnings results on Feb 25, 2026. The company reported -$0.199 earnings per share for the quarter, missing the consensus estimate of -$0.007 by -$0.192.
Is Immuron Ltd overvalued?
According to Wall Street analysts Immuron Ltd’s price is currently Overvalued.
Does Immuron Ltd pay dividends?
Immuron Ltd does not currently pay dividends.
What is Immuron Ltd’s EPS estimate?
Immuron Ltd’s EPS estimate is >-0.01.
How many shares outstanding does Immuron Ltd have?
Immuron Ltd has 8,166,340 shares outstanding.
What happened to Immuron Ltd’s price movement after its last earnings report?
Immuron Ltd reported an EPS of -$0.199 in its last earnings report, missing expectations of -$0.007. Following the earnings report the stock price went up 17.103%.
Which hedge fund is a major shareholder of Immuron Ltd?
Currently, no hedge funds are holding shares in IMRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Immuron Ltd
Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.02% Other Institutional Investors
99.98% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---